Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 randomized open-label study of NXT007 versus emicizumab prophylaxis in hemophilia A
CTR20262338Phase 3Active
- Sponsor
- Roche
- Start
- Jun 2026
- Modality
- Bispecific Antibodies → Multispecific Antibodies → Engineered Antibody Formats → Antibody-Based Therapeutics, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
A Phase 3 trial of zemocimig, emicizumab in hemophilia A, sponsored by Roche. Started Jun 2026; status: active.
02
Drugs
zemocimigemicizumab
03
Conditions
hemophilia A
Beyond the preview
Go deeper on CTR20262338.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20262338.